Cytosorbents (CTSO) Change in Accured Expenses (2010 - 2026)

Cytosorbents (CTSO) has reported Change in Accured Expenses for 17 consecutive years, with $221000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses rose 3057.14% year-over-year to $221000.0; the trailing twelve-month figure through Jun 2026 stood at -$33000.0 (up 75.74% YoY), and the FY2025 full-year result was -$706000.0, up 60.95% from the prior year.
• Change in Accured Expenses climbed to $221000.0 in Q2 2026 per CTSO's latest filing, from $92000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.4 million in Q4 2024 and bottomed at -$1.3 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$213478.4 across 5 years, with a median of -$272603.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses slumped 490.9% in 2022, then jumped 3057.14% in 2026.
• Over 5 years, Change in Accured Expenses stood at -$206441.0 in 2022, then soared by 371.1% to $559666.0 in 2023, then jumped by 142.64% to $1.4 million in 2024, then tumbled by 139.69% to -$539000.0 in 2025, then soared by 141.0% to $221000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $221000.0, $92000.0, and -$539000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.